AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast CancerGlobeNewsWire • 11/14/23
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and WebcastGlobeNewsWire • 11/09/23
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian CancerGlobeNewsWire • 11/08/23
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingGlobeNewsWire • 10/30/23
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline ProgramsGlobeNewsWire • 10/17/23
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and CareGlobeNewsWire • 09/22/23
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative BreGlobeNewsWire • 09/11/23
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading StatementsBusiness Wire • 08/23/23
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline UpdateGlobeNewsWire • 08/15/23
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and WebcastGlobeNewsWire • 08/09/23
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsGlobeNewsWire • 08/08/23
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its AffiliatesGlobeNewsWire • 07/18/23
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsGlobeNewsWire • 07/10/23
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewsWire • 07/05/23
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer ResearchGlobeNewsWire • 06/27/23
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic CanGlobeNewsWire • 06/27/23
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestGlobeNewsWire • 06/14/23
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP DevelopmentsGlobeNewsWire • 06/12/23
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline UpdateGlobeNewsWire • 05/15/23
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and WebcastGlobeNewsWire • 05/09/23
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D.GlobeNewsWire • 04/12/23
